AstraZeneca has strengthened its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.
Under this agreement, the companies will initially progress four programmes, which utilise CSPC’s advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.
AstraZeneca will receive exclusive global rights outside of China to CSPC’s once-monthly injectable weight management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into phase 1 and three preclinical programmes with differing mechanisms designed to provide extended therapeutic benefits for people living with obesity and weight-related conditions.
AstraZeneca has optionality to pursue future metabolic programmes leveraging CSPC’s proprietary LiquidGel once-monthly dosing platform technology and holds rights to deploy this across internal development programmes, broadening the potential applications of their sustained-release formulation.
This could help improve treatment adherence and support strong patient preference for once-monthly regimens.
This collaboration complements AstraZeneca’s existing weight management portfolio which includes a growing pipeline of next generation treatments to address the complexities of obesity, and weight-related complications, pursuing multiple modalities and pathways in order to tailor treatment based on individual needs.
This includes elecoglipron (formerly AZD5004), a small molecule oral GLP1RA; AZD6234 a weekly injectable selective amylin receptor agonist (SARA); and AZD9550 a weekly injectable dual GLP-1/glucagon receptor agonist, as well as a number of preclinical assets.
Financial considerations
For access to eight programmes, as well as the advanced AI molecular design capabilities and their proprietary LiquidGel once-monthly dosing platform technology, CSPC will receive an upfront payment of $1.2 billion from AstraZeneca.
CSPC is also eligible to receive development and regulatory milestones of up to $3.5 billion across all programmes. CSPC will also be eligible for further commercialisation and sales milestones plus tiered royalties.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory clearances.
Under the agreement, CSPC will progress ongoing development of the four programmes through phase 1 completion, alongside the four new programmes.
Following successful completion of phase 1, AstraZeneca will be responsible for further development and commercialisation in all territories outside of China.
CSPC retains all rights for China, Taiwan, Hong Kong and Macau, and following successful approval, AstraZeneca has the right to opt-in to co-commercialise these products.
This agreement builds on existing strategic collaborations between AstraZeneca and CSPC.
References
- World Obesity Federation. Prevalence of obesity [Internet]. London: World Obesity Federation; 2024. Available from: https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity [Last accessed: January 2026]
- World Health Organization. Obesity and overweight [Internet]. Geneva: World Health Organization; 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Last accessed: January 2026]
- Ali MM, et al. Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD). J Clin Trans Endocrinol. 2024;36:100341
- AstraZeneca. Data on file. 2024. REF-242321
